# Pizarra — PT-pseudo_2b3ef1d3a505 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2b3ef1d3a505
Task: 1

Encounter: Urology - outpatient on 23 Jan 2025.
Referrer: Dr. R. Visser (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 4.2 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.06 ng/mL²
  - PSA velocity: 0.66 ng/mL/yr
  - Prior PSA: 3.7 ng/mL
  - Prostate volume: 69.0 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.81166416 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: COPD
  - Problem list / PMHx: COPD
  - Current medication: tiotropium, salbutamol PRN
  - Allergies: NKA
  - Additional notes: PSA 4.2 ng/mL. PI-RADS 5. PSAD 0.06. Prostate volume 69 mL. DRE nodus. csPCa 0.81.

Vitals: weight 66 kg, height 185 cm, BMI 19.3, BP 113/72 mmHg, HR 74 bpm. Smoking: Ex-smoker (30 pack-yr, quit 2015).

Chief complaint: Ascending prostate-specific antigen levels and a previous positive biopsy necessitate this clinical review.

History: A 67-year-old mechanical engineer, the patient first registered a prostate-specific antigen level of 2.5 ng/mL during mid-2023. Ongoing surveillance tracked a consistent climb to 4.2 ng/mL, leading to this assessment after an earlier biopsy yielded ISUP Grade Group 1 results. Current complaints include moderate lower urinary tract symptoms, quantified at an IPSS score of 9 out of 35, which remain under conservative management. He resides independently despite being married. A former smoker, he accumulated 30 pack-years before ceasing tobacco use in 2015. His weekly alcohol consumption reaches 31 units, balanced by light weight-training sessions twice each week. Chronic obstructive pulmonary disease requires tiotropium alongside PRN salbutamol. Recent visits covered gastroenterology for a surveillance colonoscopy, pulmonary function testing, and endocrine screening for thyroid status. He reports mild bilateral hearing loss and requests written consultation summaries. Stable right knee osteoarthritis, stemming from a workplace injury decades ago, also requires management.

Physical examination: DRE — texture: firm and irregular; mobility: fixed; asymmetry: pronounced in the right mid-gland region, consistent with a distinct Nodus. General assessment shows stable vital parameters (blood pressure 113/72 mmHg, heart rate 74 bpm) and clear bilateral lung fields. Peripheral lymphadenopathy and hepatosplenomegaly are absent.

Patient info: mechanical engineer; Married; Lives alone.
Next of kin: Nephew.

Lifestyle: alcohol 31 units / week (heavy); exercise Light weight-training at home, 2x/week; IPSS score: 9/35 (moderate LUTS).

Recent other appointments: Gastroenterology — surveillance colonoscopy; Pulmonary function test — known COPD follow-up; Endocrine — thyroid screening.
Admin: Hard of hearing — speak clearly; prefers written summaries.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: NO BIOPSY
  p(biopsy = yes) = 0.45 +/- 0.20   (95% CI 0.10-0.83)

Where the uncertainty comes from:
  - aleatoric  dA = 0.16  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 6.6 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=4.2, age=67.0, psad=0.06, dre_ord=1.0, vol=69.0, n_pmhx=1.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered the visible panel data (PI-RADS=5, PSA=4.2, prior positive biopsy, csPCa probability=0.81166416) and failed to incorporate the PSA velocity (0.66 ng/mL/yr), the PSA density (0.06 ng/mL²), and the specific context of the prior positive biopsy (ISUP Grade Group 1).

WHY THE SUGGESTION COULD BE WRONG
The prior suggested NO BIOPSY with a wide uncertainty interval (0.45 +/- 0.20). This wide interval suggests the classifier cannot distinguish between the two outcomes, which is precisely what EXPERT-PROTOCOL noted: the panel is undetermined. The prior fails to account for the guideline criterion that requires reviewing retrieved documents to settle the case, especially given the high PI-RADS 5 score and rising PSA.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - what is the trend beyond the headline value?
laboratory panel - what are the full lab results?
previous GP / urology notes - what was the status of the prior biopsy?

GUIDELINE ANCHOR
The guideline search indicates that the decision should depend on the documented prior grade, whether the lesion changed against a previous MRI, and whether a surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_2b3ef1d3a505", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Institution: Ziekenhuis Gelderse Vallei, Ede | Date: 15 January 2025\n\nClinical indication: Assessment of an elevated prostate-specific antigen level of 4.2 ng/mL alongside a history of a previously positive biopsy.\n\nFINDINGS:\nThe gland measures 69.0 mL. High b-value DWI sequences highlight marked restricted diffusion, corroborated by correspondingly low ADC values, within a focal hypointense abnormality measuring roughly 18 x 15 x 12 mm situated at the mid-gland level of the right peripheral zone. Dynamic contrast-enhanced imaging captures early, focal enhancement. The neurovascular bundles remain intact. No definitive extraprostatic extension or seminal vesicle invasion is apparent.\n\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-peripheral zone. Prostate volume 69.0 mL. PSAD 0.06 ng/mL/mL. csPCa predicted probability 0.81166416."}
get_psa_trend
{"case_id": "PT-pseudo_2b3ef1d3a505", "psa_trend": [{"date": "Jun 2023", "val": 0.8}, {"date": "Dec 2023", "val": 2.2}, {"date": "Jul 2024", "val": 0.7}, {"date": "Jan 2025", "val": 4.2}]}
get_previous_notes
{"case_id": "PT-pseudo_2b3ef1d3a505", "previous_notes": [{"date": "29 Jan 2024", "author": "Dr. R. Visser (GP)", "text": "A December 2023 reading of 3.0 ng/mL triggered a follow-up test to monitor the rising trend. The patient received lifestyle guidance, with documentation noting a 4.0 ng/mL assessment threshold."}, {"date": "02 Aug 2023", "author": "Dr. R. Visser (GP)", "text": "An initial measurement of 2.5 ng/mL sparked a differential between benign enlargement and early malignancy. A subsequent PSA check was booked for mid-2024, coinciding with standard health screenings."}]}
get_lab_results
{"case_id": "PT-pseudo_2b3ef1d3a505", "laboratory_results": [{"name": "PSA", "val": "4.2 ng/mL", "date": "09 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "0.88 ng/mL", "date": "09 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "21%", "date": "09 Dec 2024", "flag": ""}, {"name": "Haemoglobin", "val": "16.0 g/dL", "date": "09 Dec 2024", "flag": ""}, {"name": "WBC", "val": "6.2 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "221 x10^9/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "82 umol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "09 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "8.3 nmol/L", "date": "09 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "97 U/L", "date": "09 Dec 2024", "flag": ""}, {"name": "LDH", "val": "196 U/L", "date": "09 Dec 2024", "flag": ""}]}

NOT RETRIEVED
a) IsUP grade group or Gleason score: The prior biopsy result was documented as ISUP Grade Group 1.
b) Does the MRI report compare with an earlier study, and is the lesion new, unchanged, or larger?: The MRI report describes a PI-RADS 5 lesion, but does not explicitly state if it is new or changed compared to a previous study.
c) Is the patient on an active surveillance pathway, and is a protocol biopsy due?: The previous notes do not explicitly state the current surveillance protocol status or if a re-biopsy is due.
d) Is any treatment, staging scan, or further procedure already planned or already declined?: Unknown.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion in the right mid-peripheral zone.
- PSA trend: Rising from 0.7 ng/mL (Jul 2024) to 4.2 ng/mL (Jan 2025), with a velocity of 0.66 ng/mL/yr.
- Previous notes: The patient is undergoing a re-evaluation due to a previous positive biopsy.

AGAINST sampling this patient now:
- Previous notes: The prior biopsy yielded ISUP Grade Group 1 results.

WHERE THIS LEANS
The evidence strongly suggests sampling is warranted due to the high PI-RADS 5 score and the significant rise in PSA, which contradicts the benign nature suggested by the prior Grade Group 1 result. This leans towards a recommendation for biopsy.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: borderline)

Although the prior biopsy yielded an ISUP Grade Group 1 result, the high PI-RADS 5 score and the significant PSA velocity of 0.66 ng/mL/yr strongly suggest that the current lesion warrants further tissue characterization. The PSA trajectory and high imaging score push the decision toward sampling, as the retrieved documents do not document a reason to defer.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=noted, pirads=decisive, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
